Avastin news from FierceBiotech
NewsRoche CEO: Emphasizing drugs for primary care
The new CEO at Roche is sending out some strong signals that the pharma giant's development process will include more new therapies for primary care. Roche is a big player in the field of Read more...
ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...
> Genta announced that it has struck definitive agreements with investors to place senior secured convertible notes due in 2010 totaling in aggregate up to $40 million in gross proceeds before Read more...
SPOTLIGHT: Avastin leaves ASCO ahead of Erbitux
Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Read more...
Kennedy's surgery may be followed by experimental therapy
Legendary Duke neurosurgeon Dr. Allan Friedman is scheduled to remove Senator Ted Kennedy's brain tumor this morning, and there's already significant speculation that the lawmaker will undergo Read more...
A deluge of pre-ASCO data hits the market
As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...
Antisoma buys Xanthus for $52M
Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial Read more...
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
Avastin, Erbitux battle for lung cancer market
Genentech's stock was down this morning on results from a Phase III study of Avastin for non-small cell lung cancer. While the drug did meet the primary endpoint--an improvement in progression-free Read more...
Experts debate FDA signals on cancer drug approval
When is a cancer therapy good enough? The Boston Globe examines answers to that question following the recent controversy over the FDA's decisions in the field. Most recently, Avastin gained a new Read more...
AstraZeneca's Recentin fails lung cancer trial
AstraZeneca says it will push ahead with late-stage studies of Recentin for colorectal cancer after shelving plans for a Phase III in non-small cell lung cancer due to toxicity concerns. The Read more...
| Press ReleasesPRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... PRESS RELEASE: Genentech, Says Avastin Shows Promise for Brain Cancer Genentech, Says Avastin Shows Promise for Brain Cancer DALLAS -- Genentech today announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin® (bevacizumab) Read more... PRESS RELEASE: Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to Read more... PRESS RELEASE: Genentech Announces Resubmission of sBLA for Avastin in Combination with Paclitaxel Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer Genentech announced Read more... |
Get more Avastin coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends